PreludeDx Publishes Independent Validation of AidaBREAST Test in npj Breast Cancer

PreludeDx Validates AidaBREAST for Breast Cancer Risk Assessment

PreludeDx, recognized as a leader in precision diagnostics, has solidified its reputation further with the recent announcement of independent validation results for the AidaBREAST® test. This pioneering multi-omic biosignature aims to predict a woman's 10-year risk of locoregional recurrence following breast-conserving surgery and her potential benefits from adjuvant radiation therapy.

Background of the AidaBREAST Test

The test assesses women diagnosed with early-stage HR+/HER2- invasive breast cancer, providing data crucial for tailoring treatment decisions. In an independent study conducted at the Royal Melbourne Hospital in Australia, researchers evaluated the efficacy of the AidaBREAST test on a cohort of 426 women who had undergone breast-conserving surgery and were prescribed endocrine therapy, with or without subsequent radiation therapy. Notably, the publication of these findings in npj Breast Cancer, a journal under the esteemed Nature Portfolio, marks a significant step in breast cancer research and treatment.

Significance of the Study

Dr. Bruce Mann, the Head of Breast Surgical Research and Principal Investigator of the study, highlighted the validation's importance. He noted, "This independent blinded validation provides essential confirmation of AidaBREAST's ability to assess locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer." This validation helps shift the conversation towards personalized care, allowing physicians and patients to engage more meaningfully regarding the necessity and benefits of radiation therapy.

Understanding AidaBREAST's Mechanism

The AidaBREAST test stands out as the first and only clinical tool that provides both prognostic and predictive insights specific to radiation therapy in stage I and IIa breast cancer. It stratifies women into Low Risk and Elevated Risk groups, enabling healthcare professionals to determine the likelihood of significant therapeutic benefits based on an individual’s tumor biology. Data demonstrates that women categorized in the Low Risk group show low 10-year recurrence rates, regardless of whether they pursue radiation therapy.

Integration with Existing Technologies

The release of these findings follows the AidaBREAST's recent recognition as an FDA Breakthrough Device—a title that reflects its potential in reshaping breast cancer treatment protocols. Dan Forche, President and CEO of PreludeDx, remarked on this milestone, stating, "Together, these milestones reflect our mission to advance personalized, biology-driven decision support for women with early-stage invasive breast cancer and the physicians who care for them."

AidaBREAST aims to expand its approach systematically, with future evaluations planned for endocrine therapy and chemotherapy benefits, ideally allowing for a more integrated decision-support tool that encompasses all aspects of early-stage breast cancer management.

Commitment to Innovation

Troy Bremer, PhD, Chief Scientific Officer of PreludeDx, expressed the innovative spirit behind AidaBREAST, emphasizing its role in capturing various dimensions of tumor biology through an advanced multi-omic approach. This technology facilitates the integration of RNA expression and spatial proteomic expression to present comprehensive tumor assessments.

AidaBREAST builds on PreludeDx's previous success with DCISionRT®, a test that significantly influenced radiation therapy decision-making for patients diagnosed with ductal carcinoma in situ (DCIS). As PreludeDx continues to innovate within the breast cancer diagnostics field, its dedication to delivering biologically driven decision-support tools remains unshaken.

Conclusion

In conclusion, the validation of the AidaBREAST test alongside its FDA recognition solidifies PreludeDx's leading role in the landscape of breast cancer diagnostics. With a commitment to advancing personalized medicine, PreludeDx is not only enhancing patient outcomes but also changing the dialogue surrounding treatment options for women facing early-stage invasive breast cancer. As these innovations unfold, they promise to play a pivotal role in the future of oncology care.